The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
about
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end pointsReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsThe Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemiaVEGF is an essential mediator of the neurogenic and behavioral actions of antidepressantsGenetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.Natural products active in aberrant c-Kit signaling.Vascular endothelial growth factor signaling in hypoxia and inflammation.Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies.Novel therapies for renal cell carcinoma.SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.Class III receptor tyrosine kinases: role in leukaemogenesis.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.Clinical impact of novel treatment strategies.Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.Therapies directed at vascular endothelial growth factor.The role of VEGF in normal and neoplastic hematopoiesis.Novel FLT3 tyrosine kinase inhibitors.Leukemic cells and the cytokine patchwork.Emerging treatments in acute myeloid leukaemia.Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterizationThe immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.FLT3 inhibitors: a story of the old and the new.Changing pathology with changing drugs: skin cancer.Targeting the vascular endothelial growth factor in hematologic malignancies.NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells.Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparinSoluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics.Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.A platinum(II) phenylphenanthroimidazole with an extended side-chain exhibits slow dissociation from a c-Kit G-quadruplex motif.Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.Vegf signaling promotes vascular endothelial differentiation by modulating etv2 expression.Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.
P2860
Q24651047-76693287-10A5-4152-9145-B08FC5B864D6Q26740953-82A8006B-E1AB-45FA-ADB7-D82A36663E63Q28300267-26EBA84A-F8DB-42C9-9B46-EEAEC8A0CF1FQ28579192-9863DA2C-2F8B-492D-A0EF-3890717A929FQ33270804-81D87946-C236-405B-988E-777AE0E8B6E8Q33286316-6A1CCF68-A03E-4234-96DC-C10A665B5FD2Q33721685-0DE68C88-0390-4C09-B0E0-D0A1ECC4E49FQ34193426-B1327B33-9FD1-43CD-AE6A-A50D8AC10EC3Q34481460-BA697E4F-3DE0-4EEC-AB01-2FA7B087235EQ34493854-02447AB8-5D58-4403-BC48-F08FA2437282Q34557003-91A5AEFD-CCD8-430B-985C-71613F027302Q34630777-B9BBBDBA-A038-4D88-BE5E-19E3D4EC120FQ34660821-C9984977-3C82-4260-B725-17C48CD53FD1Q34936052-52E6E7EE-3621-415D-8001-197D0A72A1B6Q34974876-A79685C1-101B-4FF5-AB41-D1DB9559C18CQ34997498-B4D3DF0D-86E6-48AA-BB68-B78934FF2C8FQ35011885-D55575D1-E9F6-4FAE-9C61-36EA93F9E052Q35052515-DA1FEB63-03B1-4E6A-8D94-B6C93D76BC56Q35594041-1F83BA1F-4589-4E3C-8585-B5E10A9D1D5FQ35643667-E00044A0-8BDA-449C-8C1D-D732A78CEC89Q35779278-90129A8A-9C15-48E2-8AD5-1FDCBDB2DFD7Q35782893-07303CEB-33D2-47AD-93DF-2AAA4AD4E55AQ35994847-79FA9A8E-872E-40D9-B429-21C342EF3243Q36960380-C347E629-9368-4540-BAA6-5A3DC9352804Q37098747-CCCF061F-79A4-4610-88C9-3DBBEAEBC4BCQ37183513-78EA3961-924E-4945-AF00-3CE67B21FF84Q37829880-6BCC8D2E-4FFF-4D4A-8334-68C7D1CB072DQ37890206-AC08ECE3-F80F-42A5-AC03-8C270BBA563DQ38038645-F636DF98-6A13-4F02-9939-8688304FAD42Q39808087-CFAFE57E-575F-4EAA-8B2D-1D7305380CF8Q40196292-D73AA232-7F0D-4289-AC9D-E35AAE717B6AQ40661233-9770891E-55A3-4796-AB64-40C306CCCF5EQ43838003-0658C099-0DDA-4626-9F0A-EA6A4DDC1934Q43844100-5F94DED2-6DB5-4457-BC69-F401AE266631Q44100780-670950F2-6C98-4C30-9F1C-2F63561E2327Q46038713-A6C74611-62F5-493E-84A5-3008A64D35A4Q47273203-697BFC75-363A-4046-BF47-D1BE8BA4D9A8Q50451694-DAAE3FE2-33D2-4867-9AF9-113ABAC6FD59Q52546968-25AB05EB-D415-4C1B-911D-BDBD3B4341E1Q53265540-A3F7750E-6812-4140-9026-ABF1819D2611
P2860
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@ast
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@en
type
label
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@ast
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@en
prefLabel
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@ast
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@en
P2093
P356
P1433
P1476
The antiangiogenic protein kin ...... acute myeloid leukemia blasts.
@en
P2093
P304
P356
10.1182/BLOOD.V97.5.1413
P407
P577
2001-03-01T00:00:00Z